Big Stake Penny Stock PGFY, TWTR big Rebound, GRPN, IDRA up

Retweeted by Patriot Identity

Daily Stock Deals @TOP10STOCKS  

High Stakes $PGFY, $TWTR Rebounds $GRPN $IDRA Up, update http://www.dailystockdeals.com/  #hotstocks #pennystocks @247Alerts @TOP10STOCKS @TOP10picks

Hot Stock Picks for 10/04/2013: ZOOM,DSCO,IDRA, QUIK, Profit from our insight! Get Daily Stock Deals and Alerts

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Best Stock Picks for 07/12/2013: CPRX,RSOL,IDRA,get fresh stock picks everyday, sign-up/follow us

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Stock List for o5/29/2013, Don't miss, IBIO, IDRA, STP. Penny Stock Picks,PRKA, BLDA, CTLE, NANI, WDAS, fresh picks everyday!

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

2 Hot Biotechnology stocks for 04/01/2013,IDRA, HEB

Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program.

Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system.
http://www.dailystockdeals.com/topten/hot-biotechnology-stocks-idra-04-01-2013
Source: company, OxBridge Research, Daily Stock Deals
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (IDRA) today announced that it has completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that its protocol for a Phase 2 study of IMO-8400 in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9, and is in clinical development for the treatment of autoimmune diseases.
During the first quarter of 2013, the Company completed the escalating single-dose portion of the Phase 1 trial of IMO-8400 and has now completed patient dosing in the multiple-dose portion of the trial. The multiple-dose portion of the trial involved two dose levels of IMO-8400, 0.3 and 0.6 mg/kg, and placebo, with six subjects receiving each treatment of four weekly doses. The Company expects to report top-line data from the multiple-dose portion of the trial later in the second quarter of 2013.
Source: company, OxBridge Research, Daily Stock Deals
HEB, Hemispherx Biopharma
Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, an experimental drug under clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, an experimental low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
Source: company, OxBridge Research, Daily Stock Deals

IDRA, PGNX today's bio-pharma winners,03/15/2013

Progenics Pharmaceuticals, PGNX

Fourth quarter revenue totaled $8.9 million, up $6.7 million from the 2011 period, resulting primarily from the partnering transactions. For the full year, Progenics reported revenues of $14.0 million, compared to $84.8 million for 2011, a decrease primarily from 2011 recognition of the Salix collaboration.
Royalty income for the quarter was $0.8 million compared to $1.3 million in the fourth quarter of 2011, reflecting stocking activity in 2011. Royalty income for the year was $5.0 million compared to $3.0 million for 2011.
Net sales reported to Progenics by Salix (in millions):

	Three Months Ended			Year Ended
	December 31,		September 30,	December 31,
	2012	2011	2012	2012	2011
U.S.	$4.1	$8.0	$3.8	$29.2	$21.5
Ex-U.S.	1.1	0.8	1.1	4.0	5.5
Global	$5.2	$8.8	$4.9	$33.2	$27.0

Fourth Quarter Highlights

• Completed underwritten public offering of 12,650,000 primary common shares resulting in $23.3 million net proceeds.
• Out-licensed C. difficile preclinical program for $5.0 million upfront payment (received in January) with potential future milestones and royalties.
• Fourth quarter Relistor global net sales increased 8% from the third quarter, but decreased 40% from the prior year period due to 2011 stocking activity. Annual Relistor global net sales increased 23% over 2011.
  

Recent Events

• Acquired Molecular Insight Pharmaceuticals, expanding our oncology pipeline with diagnostic and small molecule therapeutic candidates targeting PSMA and prostate cancer.
• Reported positive clinical data from a study of two novel radiolabeled small molecule imaging agents -- ¹²³I-MIP-1072 and ¹²³I-MIP-1095 -- targeting PSMA.
  

Idera Pharmaceuticals (IDRA)



Financial Results
As of December 31, 2012, cash and cash equivalents totaled $10.1 million compared to $24.6 million at December 31, 2011.
Fourth Quarter Results
Net loss applicable to common stockholders for the three months ended December 31, 2012 was $6.5 million, or $0.24 per diluted share, compared to net loss applicable to common stockholders of $9.7 million, or $0.35 per diluted share, for the same period in 2011. There was no significant revenue recognized in the fourth quarter of 2012 or 2011. Research and development expenses for the three months ended December 31, 2012 totaled $3.1 million compared to $5.7 million for the same period in 2011. General and administrative expenses for the three months ended December 31, 2012, totaled $1.3 million compared to $1.5 million for the same period in 2011.
Full Year Results
Net loss applicable to common stockholders for the year ended December 31, 2012 was $22.5 million, or $0.81 per diluted share, compared to net loss applicable to common stockholders of $28.3 million, or $1.03 per diluted share, for 2011. Total revenues in each of the years ended December 31, 2012 and 2011 were $0.1 million. Research and development expenses for the year ended December 31, 2012 totaled $13.7 million compared to $18.0 million for 2011. General and administrative expenses for the year ended December 31, 2012 totaled $6.3 million compared to $7.9 million for 2011.

Source: the company, OxBridge Research Daily Stock Deals

Top 10 Stock Picks for the New Year's Eve!

Happy New Year!

We bid farewell to 2012 and welcome the dawn of 2013 with good wishes and much success to our members, visitors and all the people around the world.

Our unique platform has been a success, during the year 2012 our membership has increased dramatically. Traders/investors are benefiting from our daily deals Everyday.

We would like to thank specially to those members who took the time to send us their feed back and valuable advice on how to improve our services, so members could benefit more. We always welcome your thoughts and comments.

We determine to continue to improvise and extend our offerings and bring more fresh deals to you. This unique platform wouldn't have been a success without your participation. Thank you.

Top 10 Stock Picks for the New Year's Eve!

1.AAMC 2.LXRX 3.VICL 4.IDRA 5.ALVR 6.COOL 7.TBOW 8.PPHM 9.IDIX 10.AMRS

Get Top Picks at one place, Every Day, All Day!

Just Picks! We Pick You Decide!

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®